Boundless Bio, Inc. (BOLD) Stock Score, Valuation & Financial Research

Boundless Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BOLD

Boundless Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.57. These figures are a research snapshot, not a buy or sell recommendation.

What Boundless Bio, Inc. does

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Boundless Bio is a clinical-stage oncology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future collaborations to fund the research and development of its proprietary ecDNA-directed therapies (ecDTx) for oncogene-amplified cancers.

Products and services

  • The company is developing a pipeline of ecDNA-directed therapies, including BBI-355, BBI-825, and BBI-940, which are designed to target the unique vulnerabilities of cancer cells driven by extrachromosomal DNA.

Customer types

Oncology patients with oncogene-amplified tumors.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for clinical trial management, data collection, and the manufacturing of drug candidates for preclinical and clinical studies. Source

Competitors and product-market comparisons

  • Biopharmaceutical and biotechnology companies — The company competes with various entities developing oncology therapeutics, including those focused on precision medicine, targeted therapies, and gene editing technologies. Source

Business strengths to evaluate

  • Proprietary Spy platform for identifying and targeting ecDNA-driven cancer vulnerabilities Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of clinical-stage product candidates Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BOLD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.57
Market capitalization:
57.76M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -64.01M
Free cash flow:
USD -47.21M
Cash:
USD 20.21M
Total debt:
USD 49.04M
EPS:
USD -2.86

What stands out

  • Free cash flow is USD -47.21M, negative for the stored period.
  • The balance sheet shows USD 20.21M of cash versus USD 49.04M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 28.82M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BOLD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BOLD fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is BOLD's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for BOLD to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of BOLD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research BOLD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.